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Patients with AF often have multimorbidity (the presence of �2 concomitant chronic
conditions).
Objective
To describe baseline characteristics, patterns of antithrombotic therapy, and factors associ-
ated with oral anticoagulant (OAC) prescription in patients with AF and�2 concomitant,
chronic, comorbid conditions.
Methods
Phase III of the GLORIA-AF Registry enrolled consecutive patients from January 2014
through December 2016 with recently diagnosed AF and CHA2DS2-VASc score�1 to
assess the safety and effectiveness of antithrombotic treatment.
Results
Of 21,241 eligible patients, 15,119 (71.2%) had�2 concomitant, chronic, comorbid condi-
tions. The proportions of patients with multimorbidity receiving non-vitamin K antagonist
oral anticoagulants (NOACs) and vitamin K antagonists (VKA) were 60.2% and 23.6%,
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respectively. The proportion with paroxysmal AF was 57.0% in the NOAC group and 45.4%
in the VKA group. Multivariable log-binomial regression analysis found the following factors
were associated with no OAC prescription: pattern of AF (paroxysmal, persistent, or perma-
nent), coronary artery disease, myocardial infarction, prior bleeding, smoking status, and
region (Asia, North America, or Europe). Factors associated with OAC prescriptions were
age, body mass index, renal function, hypertension, history of cerebral ischemic symptoms,
and AF ablation.
Conclusion
Multimorbid AF patients prescribed NOACs have fewer comorbidities than those pre-
scribed VKAs. Age, AF pattern, comorbidities, and renal function are associated with OAC
prescription.
Introduction
Atrial fibrillation (AF) affects approximately 3% of adults and its prevalence and incidence are
rising [1] with the aging of the population [2]. Older patients with AF often have other chronic
conditions that affect their clinical course [3]. Multimorbidity (the presence of�2 concomi-
tant chronic conditions) demands a holistic and integrated approach to patient care [4] since
these patients face higher risks of stroke and bleeding than those without comorbidities [5, 6].
The interplay between comorbidity, AF, and optimal thromboprophylaxis has both medical
and economic implications [7]
The aim of this analysis of the GLORIA-AF dataset is to describe baseline characteristics
and antithrombotic therapy prescription patterns in patients with AF and multimorbidity and
to identify factors associated with the selection of an oral anticoagulant (OAC) type for these
complex patients.
Materials and methods
The design of the GLORIA-AF registry (https://clinicaltrials.gov/ct2/home; trial registration
numbers NCT01468701, NCT01671007, NCT01937377) has been reported [8]. The study
protocol is concordant with the ethical guidelines of the 1975 Declaration of Helsinki, and
informed consent was obtained from each patient before enrollment.
The registry collected routine clinical practice data regarding patients with newly diagnosed
AF to evaluate patient characteristics influencing the selection, safety, and effectiveness of
antithrombotic therapy. Phase I was conducted before non-vitamin K antagonist oral antico-
agulants (NOACs) were available for stroke prevention in AF. Phase II began when dabigatran
was approved in countries with participating clinical centers. Baseline characteristics were col-
lected and those prescribed dabigatran were followed up for 2 years in Phase II. Phase III,
which started when dabigatran had been more widely adopted, gathered data for up to 3 years,
regardless of antithrombotic management [8].
Consecutive patients from 38 countries were enrolled between 2014 and 2016. Adult
patients with recently diagnosed nonvalvular AF (<3 months before the baseline visit; Latin
America <4.5 months) at risk of stroke (CHA2DS2-VASc score�1) achieved by any of the fol-
lowing: heart failure or left ventricular systolic dysfunction, hypertension, diabetes, prior
stroke, transient ischemic attack (TIA) or systemic embolism, myocardial infarction (MI),
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peripheral artery disease, age�65 years, or female sex, were enrolled [9]. The risks of stroke
and bleeding were assessed using the CHA2DS2-VASc and HAS-BLED (1 point is achieved by
any of the following: hypertension, abnormal renal or hepatic function, prior stroke, bleeding
or predisposition, labile International Normalised Ratio, elderly [>65 years], or concomitant
use of alcohol or anti-inflammatory medications) [10]. Antithrombotic therapy was prescribed
by the treating physicians according to local standards. This report is focused on baseline data
obtained from patients in Phase III, collected using electronic case report forms.
Statistical analysis
Baseline characteristics are summarized descriptively. Categorical variables are reported as
absolute frequencies and percentages, and continuous variables are summarized by median
(Quartile 1, Quartile 3). Baseline characteristics included stratification of patients with AF and
multimorbidity according to stroke prevention strategies (OAC vs antiplatelet vs no antith-
rombotic therapy, NOAC vs vitamin K antagonists [VKAs], and NOACs once daily [QD] vs
twice daily [BID]). Standardized differences were used to compare baseline characteristics
across various stroke prevention strategies, focusing on variables with the highest standardized
differences; differences�10% in absolute value were considered as balanced between groups
[11].
Factors associated with antithrombotic treatment choice were analyzed by log-binomial,
multivariable regression models, providing relative probability ratios for prescription (OAC vs
no OAC use, NOAC vs VKA; and by region). Missing data were handled using multiple impu-
tation, replacing missing data with multiple simulated values based on regression models to
provide comparatively unbiased estimates under the missing-at-random assumption. The pro-
cedure introduces random error to compensate for the added, imputed information. The
imputation regression models used 56 predictors to impute the missing data, and were
repeated 20 times to give 20 datasets with imputed data [12].
Confidence intervals were calculated based on likelihood ratios and Rubin’s method to
combine results across imputations. Both univariate and multivariable log-binomial regression
analyses were performed to evaluate crude as well as the adjusted probability ratios together
with 95% confidence intervals. The term “probability ratio” was used rather than “risk ratio”,
as our measure describes treatment selections rather than adverse outcomes.
All data were calculated using SAS version 9.4 (SAS Institute, Inc., Cary, NC).
Results
Of 21,241 eligible patients in this subanalysis, 15,119 (71.2%) had�2 concomitant, chronic
conditions (Table 1).
Baseline characteristics of AF multimorbid patients
Baseline characteristics of patients are summarized based on antithrombotic therapy (Table 2).
Among multimorbid AF patients, 83.8% were prescribed OACs, 11.0% were prescribed anti-
platelet therapy, and 5.2% were prescribed no antithrombotic therapy. The median (66.0, 79.0)
age was 73.0 years in the OAC group, 71.0 (63.0–79.0) years in the antiplatelet therapy group,
and 72.0 (64.0–80.0) years in the no antithrombotic therapy group. The proportions of females
in these groups were 44.5%, 41.7%, and 45.5%, respectively. The median CHA2DS2-VASc and
HAS-BLED scores were similar across the 3 groups.
Baseline characteristics of patients prescribed NOACs or VKAs are shown in Table 3. The
median age was 73.0 (66.0–79.0) years, and the proportion of females was 44% in both treat-
ment groups. There were no differences in CHA2DS2-VASc and HAS-BLED scores between
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these 2 groups. The prevalence of paroxysmal AF in patients with multimorbidity on NOACs
and VKAs was 57.0% and 45.4%, respectively. Among patients on NOACs, 38.4% had a Euro-
pean Heart Rhythm Association symptom score of I, compared with 33.3% for patients on
VKAs. A lower proportion (1.6%) of patients on NOACs had a glomerular filtration rate of
15–29 mL/min, compared with 4.4% of those on VKAs.
Cardioversion was performed in 19.9% of patients on NOACs vs 14.6% of those on VKAs.
Treatment in specialist offices was more prevalent for patients on NOACs (33.5% vs 23.8% in
the VKA group), while comorbidities such as heart failure (HF) and MI were less prevalent
among patients given NOACs.
Patient demographics, cardiovascular risk factors, comorbid diseases, AF categorization,
stroke and bleeding risks, and concomitant treatments of patients on NOACs QD vs BID are
summarized in Table 4 There were generally small differences between patients taking
NOACs QD vs BID. Previous TIA or stroke were present in 14.9% of the patients on NOACs
QD vs 21.3% of the patients on NOACs BID (Table 4).
Factors associated with OAC non-prescription in multimorbid AF patients
globally
Results from univariate analyses are presented in the S1 File. In the multivariable log-binomial
regression analysis, factors associated with prescriptions for no OAC use in multimorbid AF
patients were: type of AF (paroxysmal/persistent vs permanent), coronary artery disease
(CAD), MI, history of bleeding, smoking status (current vs nonsmoker), and region (Asia,
North America vs Europe). Factors associated with increased OAC use were: age 65–74 vs�75
years, body mass index (BMI) class (�25 vs 18.5–24 kg/m2), creatinine clearance (30–59 vs
�80 mL/min), hypertension, prior TIA or stroke, and AF ablation (Table 5).
Factors associated with OACs non-prescription in multimorbid AF
patients in Asia, Europe, and North America
Factors associated with prescriptions for no OAC use in multimorbid AF patients in Asia,
Europe, and North America are presented in S1 Table in S2 File. Factors associated with
increased OAC use are included in S1 Table in S2 File.
Table 1. Proportion of AF patients according to number of comorbid diseasesa.













aAF = atrial fibrillation.
https://doi.org/10.1371/journal.pone.0249524.t001
PLOS ONE Multimorbidity in GLORIA-AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0249524 April 14, 2021 4 / 34
Table 2. Baseline characteristics of AF multimorbid patients prescribed OAC or antiplatelets or no antithrombotic therapya.
OAC (n = 12,677) Antiplatelets (n = 1658) No Antithrombotic Therapy (n = 784)
Age (y), median (Q1, Q3) 73.0 (66.0–79.0) 71.0 (63.0–79.0) 72.0 (64.0–80.0)
Females, n (%) 5645 (44.5) 691 (41.7) 357 (45.5)
BMI (kg/m2), median (Q1, Q3) 28.0 (24.8–32.0) 26.1 (23.5–30.0) 26.1 (23.4–29.6)
Missing 123 (1.0) 17 (1.0) 8 (1.0)
Current smoker 1145 (9.0) 223 (13.4) 100 (12.8)
Alcohol abuse,�8 units/ week 866 (6.8) 85 (5.1) 54 (6.9)
Type of AF, n (%)
Paroxysmal 6810 (53.7) 1166 (70.3) 496 (63.3)
Persistent 4478 (35.3) 401 (24.2) 242 (30.9)
Permanent 1389 (11.0) 91 (5.5) 46 (5.9)
Categorization of AF, n (%)
EHRA I 4686 (37.0) 550 (33.2) 273 (34.8)
EHRA II 4025 (31.8) 563 (34.0) 270 (34.4)
EHRA III 3063 (24.2) 431 (26.0) 183 (23.3)
EHRA IV 903 (7.1) 114 (6.9) 58 (7.4)
Creatinine clearance (mL/min) (measured), median (Q1, Q3) 70.6 (52.5–95.3) 69.5 (50.9–92.4) 67.8 (49.7–90.3)
Creatinine clearance (mL/min), n (%)
<15 100 (0.8) 18 (1.1) 10 (1.3)
15–29 305 (2.4) 62 (3.7) 23 (2.9)
30–49 1848 (14.6) 252 (15.2) 136 (17.3)
50–79 4152 (32.8) 526 (31.7) 253 (32.3)
�80 4080 (32.2) 520 (31.4) 243 (31.0)
Missing 2192 (17.3) 280 (16.9) 119 (15.2)
CHA2DS2-VASc score, median (Q1, Q3) 4.0 (3.0–5.0) 4.0 (2.0–5.0) 3.0 (2.0–4.0)
HAS-BLED score, median (Q1, Q3) 1.0 (1.0–2.0) 2.0 (2.0–3.0) 1.0 (1.0–2.0)
Missing (HAS-BLED), n (%) 1234 (9.7) 134 (8.1) 69 (8.8)
Medical history, n (%)
Congestive heart failure 3509 (27.7) 487 (29.4) 215 (27.4)
Hypertension 10,989 (86.7) 1370 (82.6) 638 (81.4)
Diabetes mellitus 4021 (31.7) 510 (30.8) 226 (28.8)
Previous stroke or TIA 2347 (18.5) 336 (20.3) 159 (20.3)
Myocardial infarction 1580 (12.5) 384 (23.2) 58 (7.4)
Coronary artery disease 3017 (23.8) 745 (44.9) 149 (19.0)
Peripheral artery disease 503 (4.0) 79 (4.8) 21 (2.7)
Cancer 1671 (13.2) 167 (10.1) 115 (14.7)
Dementia 101 (0.8) 18 (1.1) 1 (0.1)
Gastric ulcer 145 (1.1) 20 (1.2) 13 (1.7)
Gastritis or duodenitis 455 (3.6) 70 (4.2) 50 (6.4)
Chronic kidney disease 3881 (30.6) 526 (31.7) 271 (34.6)
COPD 1045 (8.2) 120 (7.2) 59 (7.5)
Bleeding (after diagnosis of AF), n (%) 182 (1.4) 32 (1.9) 33 (4.2)
Bleeding on OAC, n (%) 159 (87.4) 27 (84.4) 18 (54.5)
Location of bleeding (after diagnosis of AF), n (%)�
Intracranial hemorrhage 12 (6.6) 6 (18.8) 8 (24.2)
Upper GI bleed 12 (6.6) 4 (12.5) 3 (9.1)
Lower GI bleed 25 (13.7) 6 (18.8) 5 (15.2)
GI bleed not further specified 11 (6.0) 4 (12.5) 4 (12.1)
(Continued)
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Factors associated with type of OAC use in multimorbid AF patients
globally
Factors associated with prescriptions for VKA use globally in multimorbid AF patients were:
age<75 vs�75 years, MI, congestive HF, diabetes mellitus, creatinine clearance (<60 vs�80
mL/min), S2 Table in S2 File.
Factors associated with decreased VKA use globally were: type of AF (paroxysmal/persis-
tent vs permanent), previous TIA or stroke, medical treatment reimbursement (self-pay/no
coverage vs not self-pay), S2 Table in S2 File.
Factors associated with OAC use in multimorbid AF patients in Asia,
Europe, North America, and Latin America
Factors associated with prescriptions for VKA use in multimorbid AF patients in Asia, Europe,
North America, and Latin America are presented in S3 Table in S2 File. Factors associated
with decreased prescriptions for VKA use in multimorbid AF patients in Asia, Europe, North
America, and Latin America are presented in S3 Table in S2 File.
Discussion
There are still knowledge gaps in how OACs are used in clinical practice in patients with AF
and multiple comorbidities and which factors influence OAC prescription in such patients.
Our study shows that, despite a median CHA2DS2-VASc score >3, approximately 16% of
patients with multimorbidity and AF are not anticoagulated. The baseline characteristics in
Table 2. (Continued)
OAC (n = 12,677) Antiplatelets (n = 1658) No Antithrombotic Therapy (n = 784)
Urogenital hemorrhage 31 (17.0) 3 (9.4) 3 (9.1)
Bleeding at other location 81 (44.5) 7 (21.9) 8 (24.2)
Bleeding with unknown location 10 (5.5) 2 (6.3) 2 (6.1)
Region, n (%)
Asia 1739 (13.7) 719 (43.4) 325 (41.5)
Europe 6514 (51.4) 443 (26.7) 266 (33.9)
North America 3429 (27.0) 415 (25.0) 144 (18.4)
Latin America 995 (7.8) 81 (4.9) 49 (6.3)
Type of site, n (%)
GP/primary care 686 (5.4) 171 (10.3) 77 (9.8)
Specialist office 3902 (30.8) 512 (30.9) 191 (24.4)
Community hospital 3757 (29.6) 350 (21.1) 175 (22.3)
University hospital 3878 (30.6) 543 (32.8) 326 (41.6)
Outpatient health care centre 222 (1.8) 51 (3.1) 6 (0.8)
Anticoagulation clinics 82 (0.6) 6 (0.4) 4 (0.5)
Other 150 (1.2) 25 (1.5) 5 (0.6)
aAF = atrial fibrillation; BMI = body mass index; CHA2DS2-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age�75 years, diabetes, stroke/
transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease;
EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke,
bleeding history or predisposition, labile International Normalised Ratio, elderly (>65 years), drugs or alcohol concomitantly; OAC = oral anticoagulant; Q = quartile;
TIA = transient ischemic attack; y = years.
�Proportion calculated out of Bleeding (after diagnosis of AF).
https://doi.org/10.1371/journal.pone.0249524.t002
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Table 3. Baseline characteristics of AF multimorbid patients prescribed NOACs or VKAsa.
NOAC (n = 9105) VKA (n = 3572) Standardized Difference
Age (y), median (Q1, Q3) 73.0 (66.0–79.0) 73.0 (66.0–79.0) 0.005
Females, n (%) 4072 (44.7) 1573 (44.0) –0.014
BMI (kg/m2), median (Q1, Q3) 28.0 (24.8–32.2) 27.8 (24.6–31.6) –0.066
Missing 37 (1.2) 60 (1.0) 0.020
Current smoker 812 (8.9) 333 (9.3) 0.014
Alcohol abuse,�8 units/ week 651 (7.1) 215 (6.0) –0.046
Type of AF, n (%)
Paroxysmal 5187 (57.0) 1623 (45.4) –0.232
Persistent 3052 (33.5) 1426 (39.9) 0.133
Permanent 866 (9.5) 523 (14.6) 0.158
Categorization of AF, n (%)
EHRA I 3496 (38.4) 1190 (33.3) –0.106
EHRA II 2886 (31.7) 1139 (31.9) 0.004
EHRA III 2131 (23.4) 932 (26.1) 0.062
EHRA IV 592 (6.5) 311 (8.7) 0.083
Creatinine clearance (mL/min) (measured), median (Q1, Q3) 72.1 (53.7–97.0) 66.8 (48.9–91.0) –0.078
Creatinine clearance (mL/min) n (%)
<15 50 (0.5) 50 (1.4) 0.087
15–29 148 (1.6) 157 (4.4) 0.163
30–49 1280 (14.1) 568 (15.9) 0.052
50–79 3046 (33.5) 1106 (31.0) –0.053
�80 3053 (33.5) 1027 (28.8) –0.103
Missing 1528 (16.8) 664 (18.6) 0.047
CHA2DS2-VASc score, median (Q1, Q3) 4.0 (3.0–5.0) 4.0 (3.0–5.0) 0.080
HAS-BLED score, median (Q1, Q3) 1.0 (1.0–2.0) 1.0 (1.0–2.0) 0.016
Missing (HAS-BLED), n (%) 858 (9.4) 376 (10.5) 0.037
Medical history, n (%)
Congestive heart failure 2232 (24.5) 1277 (35.8) 0.247
Hypertension 7907 (86.8) 3082 (86.3) –0.016
Diabetes mellitus 2839 (31.2) 1182 (33.1) 0.041
Previous stroke or TIA 1741 (19.1) 606 (17.0) –0.056
Myocardial infarction 1039 (11.4) 541 (15.1) 0.110
Coronary artery disease 2104 (23.1) 913 (25.6) 0.057
Peripheral artery disease 355 (3.9) 148 (4.1) 0.012
Cancer 1223 (13.4) 448 (12.5) –0.027
Dementia 76 (0.8) 25 (0.7) –0.016
Gastric ulcer 111 (1.2) 34 (1.0) –0.026
Gastritis or duodenitis 317 (3.5) 138 (3.9) 0.020
Chronic kidney disease 2663 (29.2) 1218 (34.1) 0.104
COPD 743 (8.2) 302 (8.5) 0.011
Bleeding (after diagnosis of AF), n (%) 130 (1.4) 52 (1.5) 0.002
Bleeding on OAC, n (%) 112 (86.2) 47 (90.4) 0.132
Location of bleeding (after diagnosis of AF), n (%)�
Intracranial hemorrhage 11 (8.5) 1 (1.9) –0.298
Upper GI bleed 8 (6.2) 4 (7.7) 0.061
Lower GI bleed 20 (15.4) 5 (9.6) –0.175
GI bleed not further specified 9 (6.9) 2 (3.8) –0.137
(Continued)
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these complex patients differ in relation to antithrombotic therapy selection, suggesting that
comorbidities may influence antithrombotic therapy prescription patterns for patients with
AF. For example, prescription of OACs globally in patients with AF and multimorbidity was
associated with age, BMI, cardiovascular risk factors (smoking status), AF pattern, concomi-
tant diseases (ie, hypertension, CAD, MI, previous TIA or stroke), history of bleeding, renal
function, rhythm control strategy (AF ablation and AF cardioversion), and region (Asia and
North America). Prescriptions patterns were also subject to regional differences in clinical
practice.
Patient characteristics according to antithrombotic therapy use
The results suggest that patients with AF and multimorbidity prescribed NOACs are more
likely to have paroxysmal AF, and have fewer comorbidities than those prescribed VKAs, con-
sistent with other reports [13–15]. Declining renal function may influence the choice of VKA
in those with chronic kidney disease. Healthcare system-related factors (such as center type)
also influence treatment strategies. Patients with AF and multimorbidity treated in specialist
offices and community hospitals are more often prescribed NOACs than VKAs.
The patients in this cohort prescribed antiplatelet agents had a higher risk of bleeding
according to HAS-BLED score than those who were prescribed OACs. They also more often
had paroxysmal AF compared to those prescribed OACs. Patients with AF and CAD were
more often prescribed antiplatelets than OACs despite the fact that antiplatelet therapy does
not prevent stroke or reduce mortality, elevates the risk of bleeding, and is not recommended
Table 3. (Continued)
NOAC (n = 9105) VKA (n = 3572) Standardized Difference
Urogenital hemorrhage 20 (15.4) 11 (21.2) 0.150
Bleeding at other location 56 (43.1) 25 (48.1) 0.101
Bleeding with unknown location 6 (4.6) 4 (7.7) 0.128
AF cardioversion 1814 (19.9) 521 (14.6) –0.142
Region, n (%)
Asia 1222 (13.4) 517 (14.5) 0.030
Europe 4498 (49.4) 2016 (56.4) 0.141
North America 2808 (30.8) 621 (17.4) –0.319
Latin America 577 (6.3) 418 (11.7) 0.188
Type of site, n (%)
GP/primary care 502 (5.5) 184 (5.2) –0.016
Specialist office 3053 (33.5) 849 (23.8) –0.217
Community hospital 2880 (31.6) 877 (24.6) –0.158
University hospital 2454 (27.0) 1424 (39.9) 0.276
Outpatient health care centre 72 (0.8) 150 (4.2) 0.220
Anticoagulation clinics 37 (0.4) 45 (1.3) 0.094
Other 107 (1.2) 43 (1.2) 0.003
aAF = atrial fibrillation; BMI = body mass index; CHA2DS2-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age�75 years, diabetes, stroke/
transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease;
EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke,
bleeding history or predisposition, labile International Normalised Ratio, elderly (>65 years), drugs or alcohol concomitantly; NOAC = nonvitamin K antagonist oral
anticoagulants; OAC = oral anticoagulant; Q = quartile; TIA = transient ischemic attack; VKA = vitamin K antagonists; y = years.
�Proportion calculated out of Bleeding (after diagnosis of AF).
https://doi.org/10.1371/journal.pone.0249524.t003
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Table 4. Baseline characteristics of AF multimorbid patients prescribed NOACs QD or NOACs BID.
NOAC QD (n = 3071) NOAC BID (n = 6034) Standardized Difference
Age (y), median (Q1, Q3) 72.0 (65.0–79.0) 73.0 (66.0–79.0) –0.098
Females, n (%) 1306 (42.5) 2766 (45.8) –0.067
BMI (kg/m2), median (Q1, Q3) 28.3 (25.0–32.8) 27.9 (24.8–32.0) 0.089
Current smoker 250 (8.1) 562 (9.3) –0.042
Alcohol abuse,�8 units/ week 242 (7.9) 409 (6.8) 0.042
Type of AF, n (%)
Paroxysmal 1767 (57.5) 3420 (56.7) 0.017
Persistent 1045 (34.0) 2007 (33.3) 0.016
Permanent 259 (8.4) 607 (10.1) –0.056
Categorization of AF, n (%)
EHRA I 1138 (37.1) 2358 (39.1) –0.042
EHRA II 983 (32.0) 1903 (31.5) 0.010
EHRA III 775 (25.2) 1356 (22.5) 0.065
EHRA IV 175 (5.7) 417 (6.9) –0.050
Creatinine clearance (mL/min), (measured), median (Q1, Q3) 74.4 (55.3–101.8) 70.5 (53.1–94.3) 0.041
Creatinine clearance, n (%)
<15 18 (0.6) 32 (0.5) 0.008
15–29 40 (1.3) 108 (1.8) –0.040
30–49 401 (13.1) 879 (14.6) –0.044
50–79 1018 (33.1) 2028 (33.6) –0.010
�80 1125 (36.6) 1928 (32.0) 0.099
Missing 469 (15.3) 1059 (17.6) –0.062
CHA2DS2-VASc score, median (Q1, Q3) 3.0 (2.0–4.0) 4.0 (3.0–5.0) –0.127
HAS-BLED score, median (Q1, Q3) 1.0 (1.0–2.0) 1.0 (1.0–2.0) –0.066
Missing (HAS-BLED), n (%) 302 (9.8) 556 (9.2) 0.021
Medical history, n (%)
Congestive heart failure 772 (25.1) 1460 (24.2) 0.022
Hypertension 2672 (87.0) 5235 (86.8) 0.007
Diabetes mellitus 1021 (33.2) 1818 (30.1) 0.067
Previous stroke or TIA 457 (14.9) 1284 (21.3) –0.167
Myocardial infarction 366 (11.9) 673 (11.2) 0.024
Coronary artery disease 746 (24.3) 1358 (22.5) 0.042
Peripheral artery disease 119 (3.9) 236 (3.9) –0.002
Cancer 407 (13.3) 816 (13.5) –0.008
Dementia 24 (0.8) 52 (0.9) –0.009
Gastric ulcer 40 (1.3) 71 (1.2) 0.011
Gastritis or duodenitis 116 (3.8) 201 (3.3) 0.024
Chronic kidney disease 839 (27.3) 1824 (30.2) –0.064
COPD 258 (8.4) 485 (8.0) 0.013
Bleeding (after diagnosis of AF), n (%) 57 (1.9) 73 (1.2) 0.053
Bleeding on OAC, n (%) 52 (91.2) 60 (82.2) 0.269
Location of bleeding (after diagnosis of AF), n (%)
Intracranial hemorrhage 2 (3.5) 9 (12.3) –0.331
Upper GI bleed 4 (7.0) 4 (5.5) 0.064
Lower GI bleed 10 (17.5) 10 (13.7) 0.106
GI bleed not further specified 5 (8.8) 4 (5.5) 0.128
Urogenital hemorrhage 6 (10.5) 14 (19.2) –0.245
(Continued)
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for prevention of AF-related thromboembolism [16]. Unfortunately, antiplatelet monotherapy
is still a frequent choice of prescribing physicians based on several European reports [17, 18].
Factors associated with OAC prescription in multimorbid AF patients
globally
The majority of multimorbid AF patients had a high risk of stroke (CHA2DS2-VASc score�2)
and oral anticoagulation therapy is recommended for these patients [19]. Hypertension and
HF were the most prevalent risk factors for thromboembolic complications [20] and these fac-
tors and previous stroke or TIA are associated with a greater frequency of OAC prescription.
Prescription of OACs was inversely associated with comorbidities that are strongly associated
with elevated thromboembolic risk (eg, MI, CAD), just as conditions associated with an
increased risk of bleeding (eg, previous hemorrhagic events) were associated with less frequent
prescription of OACs. This is also consistent with prior reports [13] although current clinical
practice guidelines recommend that patients with AF at a high risk of bleeding should gener-
ally continue anticoagulation with frequent visits and close monitoring [21]. A history of AF
ablation in multimorbid AF patients was associated with more frequent OAC prescription as
per guidelines [21] and consistent with other studies [22].
Younger age (�75 years) was associated with greater OAC prescription and more frequent
selection of VKAs compared to practice patterns for older patients. Several studies have sug-
gested that increasing age is a barrier to implementing OAC use [23, 24]. Importantly, stroke
risk increases with age, and the absolute benefit of OACs is clearly increased for older patients
with AF [25]. In one report, when adjusted for comorbidity, age was not an important deter-
minant of anticoagulation [26].
Table 4. (Continued)
NOAC QD (n = 3071) NOAC BID (n = 6034) Standardized Difference
Bleeding at other location 24 (42.1) 32 (43.8) –0.035
Bleeding with unknown location 6 (10.5) 0 (0.0) 0.438
AF cardioversion 710 (23.1) 1104 (18.3) 0.119
Region, n (%)
Asia 356 (11.6) 866 (14.4) –0.082
Europe 1465 (47.7) 3033 (50.3) –0.051
North America 1056 (34.4) 1752 (29.0) 0.115
Latin America 194 (6.3) 383 (6.3) –0.001
Type of site, n (%)
GP/primary care 184 (6.0) 318 (5.3) 0.031
Specialist office 1110 (36.1) 1943 (32.2) 0.083
Community hospital 921 (30.0) 1959 (32.5) –0.053
University hospital 773 (25.2) 1681 (27.9) –0.061
Outpatient health care center 19 (0.6) 53 (0.9) –0.030
Anticoagulation clinics 18 (0.6) 19 (0.3) 0.041
Other 46 (1.5) 61 (1.0) 0.044
aAF = atrial fibrillation; BID = twice daily; BMI = body mass index; CHA2DS2-VASc = congestive heart failure/left ventricular dysfunction, hypertension, age�75 years,
diabetes, stroke/transient ischemic attack/systemic embolism, vascular disease, age 65–74 years, sex category (female); COPD = chronic obstructive pulmonary disease;
EHRA = European Heart Rhythm Association; GI = gastrointestinal; GP = general practitioner; HAS-BLED = hypertension, abnormal renal /liver function, stroke,
bleeding history or predisposition, labile International Normalised Ratio, elderly (>65 years), drugs or alcohol concomitantly; NOAC = nonvitamin K antagonist oral
anticoagulants; OAC = oral anticoagulant; Q = quartile; QD = once daily; TIA = transient ischemic attack.
https://doi.org/10.1371/journal.pone.0249524.t004
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Table 5. Multivariable log-binomial analysis for factors associated with prescription of OAC therapy (no OAC vs
OAC)a,b.














Current smoker 1.14 (1.03–1.25)
Past smoker 0.91 (0.84–0.99)
Categorization of AF
EHRA I 1.0 (ref)
EHRA II 1.04 (0.96–1.12)
EHRA III 0.99 (0.91–1.07)






Coronary artery disease 1.42 (1.31–1.53)
Myocardial infarction 1.18 (1.08–1.28)
Congestive heart failure 1.01 (0.94–1.08)
Diabetes mellitus 0.95 (0.88–1.02)
Previous TIA or stroke 0.81 (0.68–0.97)
Bleeding after diagnosis of AF 1.60 (1.42–1.79)
Peripheral artery disease 1.13 (0.96–1.34)
Cancer 1.00 (0.90–1.12)
Functional dyspepsia 0.85 (0.56–1.27)
Gastric ulcer 0.91 (0.69–1.21)
Gastritis or duodenitis 0.95 (0.82–1.10)
COPD 1.03 (0.90–1.19)
Hyperthyroidism 0.96 (0.79–1.17)
Hepatic disease 1.05 (0.87–1.27)
Dementia 1.09 (0.76–1.56)
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Multimorbid AF patients with paroxysmal or persistent AF were less often prescribed
OACs in particular VKAs than those with permanent AF. NOACs should be preferred in
patients with multimorbidity and polypharmacy given their lower number of drug–drug inter-
actions compared with VKAs [27]. Ischemic stroke may occur as frequently in paroxysmal AF
as in permanent AF, especially with multiple risk factors [28]. Moreover, the use of OACs
should be based on stroke risk assessment according to the CHA2DS2-VASc risk score [21].
The pattern of AF seems to be related to patient profiles characterized by age, concomitant dis-
eases, symptoms, and risk factors for stroke and bleeding [13]. Patients with higher European
Heart Rhythm Association symptom scores were more often prescribed VKAs than those who
were asymptomatic.
Multimorbid AF patients with a history of cardioversion were less often prescribed VKAs
than those without prior cardioversion. NOACs were preferred in multimorbid AF patients
after cardioversion. A similar pattern was found in another study where rhythm control strat-
egy was associated with selection of NOAC [14].
OAC prescription in multimorbid AF patients regionally
In this study, multimorbidity influenced ATT use within particular regions. In Europe, youn-
ger patients (age <65 years) were less likely to be prescribed OACs than older patients (age
�75 years). Multimorbid AF patients with congestive HF were more likely to be anticoagu-
lated due to an increased risk of thromboembolism. In Europe, bleeding risk of a patient as
perceived by physicians may be the reason for decreased use of anticoagulation. Patients with
gastritis or duodenitis or hepatic disease are less likely to be prescribed OACs, probably
because of the elevated risk of bleeding. This association has been previously noted [26]. In
Asia, younger patients (age <75 years) were more likely to be prescribed OACs than older
patients (age�75 years). Interestingly, patients with gastritis or duodenitis or a history of can-
cer were more likely to receive OAC than those without those diseases. In North America,
Table 5. (Continued)
Factor Relative Risk (95% CI) For Prescription of No OAC Globally




North America 1.24 (1.11–1.39)
Latin America 1.14 (0.96–1.37)
Medical treatment reimbursed by
Self-pay/no coverage 0.82 (0.69–0.96)
Not self-pay 1.0 (ref)
Type of site
Specialist office 1.26 (1.14–1.39)
Community hospital 1.0 (ref)
University hospital 1.28 (1.17–1.40)
aA few other variables (alcohol abuse, psychosocial factors, biological heart valve implant, valve repair, and peptic
ulcer) are included in the multivariable log-binomial regression analysis model and are presented in the S1 File.
bAF = atrial fibrillation; BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary
disease; EHRA = European Heart Rhythm Association; OAC = oral anticoagulant; ref = reference; TIA = transient
ischemic attack.
https://doi.org/10.1371/journal.pone.0249524.t005
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younger multimorbid AF patients (age <65 years) were less likely to be prescribed OACs than
older patients (age�75 years). Multimorbid AF patients with diabetes were more likely to
receive OACs, due to their association with higher thromboembolic risk, as well as higher all-
cause, cardiovascular, and noncardiovascular mortality [29]. AF patients with multimorbidity
and cancer in North America were less likely to receive OAC.
Asia and North America were associated with decreased OAC prescription. In Asia, OACs
are less commonly prescribed in nonvalvular AF patients than in Europe, possibly because of
suspicion of the risk of bleeding during treatment [30]. Also, NOACs are not reimbursed in
some Asian countries.
Strengths
It is one the largest prospective global cohort of consecutive AF patients receiving different
antithrombotic treatments. Initiation of Phase III was region-specific, once relevant baseline
characteristics of patients initiating dabigatran and VKA therapy in Phase II overlapped based
on propensity score comparisons. After the baseline visit, all patients in this Phase III were
managed according to local clinical practice and were followed for 3 years, regardless of pre-
scribed antithrombotic therapy. This study had regular follow-up with physicians, alongside
on-site monitoring, multiple standards for data quality assurance and review.
Limitations
Although the GLORIA-AF study was designed to capture all outcome events, this analysis did
not consider follow-up data. The following limitations exist in our study: we have no data on
patient and prescriber treatment preferences; similarly, reasons for OAC nonprescription were
not reported. Furthermore, this study reflects single, initial-treatment decisions during a
period when prescribing patterns may have been changing, and the analysis was based on pre-
scription pattern shortly after entry into the registry (baseline). Neither have we accounted for
quality of anticoagulation or changes in clinical practice patterns over time.
Conclusion
AF patients with multimorbidity who were prescribed NOACs were relatively healthier, more
likely to have paroxysmal AF, and had fewer prevalent comorbidities than AF multimorbid
patients on VKAs. Multimorbidity may determine the antithrombotic therapy prescription
pattern within AF patients. Several factors are related to increased OAC prescription in multi-
morbid AF patients, including younger age, hypertension, prior TIA or stroke, and AF abla-
tion. Pattern of AF (paroxysmal and persistent AF), CAD, MI, history of bleeding, and region
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PLOS ONE Multimorbidity in GLORIA-AF


















































PLOS ONE Multimorbidity in GLORIA-AF


















































PLOS ONE Multimorbidity in GLORIA-AF



























Yannie Soo Oi Yan
Rodolfo Sotolongo





















PLOS ONE Multimorbidity in GLORIA-AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0249524 April 14, 2021 29 / 34
Yuichiro Takagi
































Philippe van de Borne
B.J. van den Berg














PLOS ONE Multimorbidity in GLORIA-AF


















































PLOS ONE Multimorbidity in GLORIA-AF















Conceptualization: Monika Kozieł, Christine Teutsch, Jonathan L. Halperin, Kenneth J. Roth-
man, Hans-Christoph Diener, Chang-Sheng Ma, Sabrina Marler, Shihai Lu, Menno V.
Huisman, Gregory Y. H. Lip.
Formal analysis: Sabrina Marler, Shihai Lu, Gregory Y. H. Lip.
Investigation: Christine Teutsch, Sabrina Marler, Shihai Lu, Venkatesh K. Gurusamy, Greg-
ory Y. H. Lip.
Methodology: Monika Kozieł, Christine Teutsch, Jonathan L. Halperin, Kenneth J. Rothman,
Sabrina Marler, Shihai Lu, Gregory Y. H. Lip.
Resources: Christine Teutsch, Venkatesh K. Gurusamy.
Software: Shihai Lu, Venkatesh K. Gurusamy.
Supervision: Hans-Christoph Diener, Menno V. Huisman, Gregory Y. H. Lip.
Validation: Jonathan L. Halperin, Kenneth J. Rothman, Gregory Y. H. Lip.
Writing – original draft: Monika Kozieł.
Writing – review & editing: Christine Teutsch, Jonathan L. Halperin, Kenneth J. Rothman,
Hans-Christoph Diener, Chang-Sheng Ma, Sabrina Marler, Shihai Lu, Venkatesh K. Guru-
samy, Menno V. Huisman, Gregory Y. H. Lip.
References
1. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the preva-
lence, incidence, management and outcome of a large contemporary cohort of patients with incident
non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4(1):e001486. https://doi.org/10.1161/JAHA.
114.001486 PMID: 25609415
2. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11
(11):639–54. https://doi.org/10.1038/nrcardio.2014.118 PMID: 25113750
3. LaMori JC, Mody SH, Gross HJ, daCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of
comorbidities among patients with atrial fibrillation. Ther Adv Cardiovasc Dis. 2013; 7(2):53–62. https://
doi.org/10.1177/1753944712464101 PMID: 23090783
4. Boyd CM, Fortin M. Future of Multimorbidity Research: How Should Understanding of Multimorbidity
Inform Health System Design? Public Health Reviews. 2010; 32(2):451–74.
5. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and
implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;
380(9836):37–43. https://doi.org/10.1016/S0140-6736(12)60240-2 PMID: 22579043
PLOS ONE Multimorbidity in GLORIA-AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0249524 April 14, 2021 32 / 34
6. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et al. Real-world evidence of stroke
prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
Curr Med Res Opin. 2016; 32(12):2047–53. https://doi.org/10.1080/03007995.2016.1237937 PMID:
27633045
7. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and
future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017; 117(7):1230–
9. https://doi.org/10.1160/TH16-11-0876 PMID: 28597905
8. Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of Global
Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry
program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;
167(3):329–34. https://doi.org/10.1016/j.ahj.2013.12.006 PMID: 24576516
9. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting
stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro
heart survey on atrial fibrillation. Chest. 2010; 137(2):263–72. https://doi.org/10.1378/chest.09-1584
PMID: 19762550
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-
BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
Chest. 2010; 138(5):1093–100. https://doi.org/10.1378/chest.10-0134 PMID: 20299623
11. Austin PC. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between
Two Groups in Observational Research. Communications in Statistics—Simulation and Computation.
2009; 38(6):1228–34.
12. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for
practice. Stat Med. 2011; 30(4):377–99. https://doi.org/10.1002/sim.4067 PMID: 21225900
13. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Contemporary stroke preven-
tion strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational
Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;
20(5):747–57. https://doi.org/10.1093/europace/eux301 PMID: 29016832
14. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, et al. Factors associated with
non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibril-
lation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II
(ORBIT-AF II). Am Heart J. 2017; 189:40–7. https://doi.org/10.1016/j.ahj.2017.03.024 PMID: 28625380
15. Proietti M, Marzona I, Vannini T, Tettamanti M, Fortino I, Merlino L, et al. Long-Term Relationship
Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. Mayo Clin Proc. 2019; 94
(12):2427–36. https://doi.org/10.1016/j.mayocp.2019.06.012 PMID: 31668449
16. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel
added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009; 360(20):2066–78. https://doi.org/
10.1056/NEJMoa0901301 PMID: 19336502
17. Proietti M, Laroche C, Opolski G, Maggioni AP, Boriani G, Lip GYH, et al. ‘Real-world’ atrial fibrillation
management in Europe: observations from the 2-year follow-up of the EURObservational Research
Programme-Atrial Fibrillation General Registry Pilot Phase. EP Europace. 2016; 19(5):722–33.
18. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. ’Real-world’ antithrombotic
treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med. 2014; 127(6):519–29.e1. https://
doi.org/10.1016/j.amjmed.2013.12.022 PMID: 24486284
19. Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for
Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154(5):1121–201. https://
doi.org/10.1016/j.chest.2018.07.040 PMID: 30144419
20. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R, et al. Oral anticoagulation use by
patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-
use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012; 107
(6):1053–65. https://doi.org/10.1160/TH11-11-0768 PMID: 22398417
21. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the
management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37
(38):2893–962. https://doi.org/10.1093/eurheartj/ehw210 PMID: 27567408
22. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Contemporary stroke preven-
tion strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational
Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018;
20(5):747–57. https://doi.org/10.1093/europace/eux301 PMID: 29016832
23. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis
using the General Practice Research Database (GPRD) 2000–2009. Heart. 2013; 99(2):127–32.
https://doi.org/10.1136/heartjnl-2012-302843 PMID: 23086966
PLOS ONE Multimorbidity in GLORIA-AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0249524 April 14, 2021 33 / 34
24. Chan PS, Maddox TM, Tang F, Spinler S, Spertus JA. Practice-level variation in warfarin use among
outpatients with atrial fibrillation (from the NCDR PINNACLE program). Am J Cardiol. 2011; 108
(8):1136–40. https://doi.org/10.1016/j.amjcard.2011.06.017 PMID: 21798501
25. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke pre-
vention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009; 40
(4):1410–6. https://doi.org/10.1161/STROKEAHA.108.526988 PMID: 19182090
26. Vanbeselaere V, Truyers C, Elli S, Buntinx F, De Witte H, Degryse J, et al. Association between atrial
fibrillation, anticoagulation, risk of cerebrovascular events and multimorbidity in general practice: a reg-
istry-based study. BMC Cardiovasc Disord. 2016; 16:61. https://doi.org/10.1186/s12872-016-0235-1
PMID: 27021333
27. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart
Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in
patients with atrial fibrillation. Eur Heart J. 2018; 39(16):1330–93. https://doi.org/10.1093/eurheartj/
ehy136 PMID: 29562325
28. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm
Cohort of Atrial Fibrillation. Eur Heart J. 2010; 31(8):967–75. https://doi.org/10.1093/eurheartj/ehn599
PMID: 19176537
29. Fumagalli S, Said SA, Laroche C, Gabbai D, Boni S, Marchionni N, et al. Management and prognosis of
atrial fibrillation in diabetic patients: an EORP-AF General Pilot Registry report. European Heart Journal
—Cardiovascular Pharmacotherapy. 2017; 4(3):172–9.
30. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Hae-
most. 2014; 111(5):789–97. https://doi.org/10.1160/TH13-11-0948 PMID: 24500243
PLOS ONE Multimorbidity in GLORIA-AF
PLOS ONE | https://doi.org/10.1371/journal.pone.0249524 April 14, 2021 34 / 34
